CL2016000880A1 - Recubrimiento farmacéutico soluble en agua con estabilidad mejorada - Google Patents

Recubrimiento farmacéutico soluble en agua con estabilidad mejorada

Info

Publication number
CL2016000880A1
CL2016000880A1 CL2016000880A CL2016000880A CL2016000880A1 CL 2016000880 A1 CL2016000880 A1 CL 2016000880A1 CL 2016000880 A CL2016000880 A CL 2016000880A CL 2016000880 A CL2016000880 A CL 2016000880A CL 2016000880 A1 CL2016000880 A1 CL 2016000880A1
Authority
CL
Chile
Prior art keywords
coating
water soluble
improved stability
soluble pharmaceutical
molding
Prior art date
Application number
CL2016000880A
Other languages
English (en)
Spanish (es)
Inventor
Anwar Siraj Daud
Nidhi Prakash Sapkal
Minal Nandkumar Bonde
Original Assignee
Zim Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zim Laboratories Ltd filed Critical Zim Laboratories Ltd
Publication of CL2016000880A1 publication Critical patent/CL2016000880A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
CL2016000880A 2013-10-14 2016-04-14 Recubrimiento farmacéutico soluble en agua con estabilidad mejorada CL2016000880A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3221MU2013 IN2013MU03221A (enExample) 2013-10-14 2014-10-13

Publications (1)

Publication Number Publication Date
CL2016000880A1 true CL2016000880A1 (es) 2017-01-27

Family

ID=53274239

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000880A CL2016000880A1 (es) 2013-10-14 2016-04-14 Recubrimiento farmacéutico soluble en agua con estabilidad mejorada

Country Status (8)

Country Link
BR (1) BR112016008356B1 (enExample)
CA (1) CA2927334C (enExample)
CL (1) CL2016000880A1 (enExample)
EA (1) EA038558B1 (enExample)
IN (1) IN2013MU03221A (enExample)
MY (1) MY184297A (enExample)
UA (1) UA123893C2 (enExample)
WO (1) WO2015083181A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3082767B1 (en) * 2013-12-17 2024-09-25 Zim Laboratories Limited Pharmaceutical microemulsion immobilized in a thin polymer matrix and methods of making them
CA3056944A1 (en) * 2017-03-30 2018-10-04 Intelgenx Corp. Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists
DE102017127452A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Wasserlösliche Polymerklebschichten
FR3082851B1 (fr) * 2018-06-25 2022-09-02 Biomerieux Sa Procede de detection et/ou d'identification d'au moins un microorganisme cible present sur une surface.
CN119015263B (zh) * 2024-08-20 2025-07-11 云南白药集团无锡药业有限公司 一种云南白药口溶膜剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5947987B2 (ja) * 1979-10-08 1984-11-22 富士写真フイルム株式会社 加筆・修正可能なマツトフイルム
US4664859A (en) * 1983-12-02 1987-05-12 Vcf Films Inc. Div. Of Pmc Process for solvent casting a film
US5272191A (en) * 1991-08-21 1993-12-21 Fmc Corporation Cold water soluble films and film forming compositions
US6966960B2 (en) * 2003-05-07 2005-11-22 Hewlett-Packard Development Company, L.P. Fusible water-soluble films for fabricating three-dimensional objects
WO2005084636A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited A process for the preparation of controlled-release pharmaceutical composition of metoprolol
WO2006080630A1 (en) * 2004-09-23 2006-08-03 Handok Pharmaceuticals Co., Ltd. Pharmaceutical combination preparation for oral delivery for the treatment of diabetes mellitus
US20090162516A1 (en) * 2007-12-21 2009-06-25 Brown Solomon E Edible, water-soluble film

Also Published As

Publication number Publication date
IN2013MU03221A (enExample) 2015-07-03
EA038558B1 (ru) 2021-09-14
EA201690751A1 (ru) 2016-08-31
MY184297A (en) 2021-03-31
WO2015083181A2 (en) 2015-06-11
CA2927334C (en) 2023-08-29
BR112016008356B1 (pt) 2022-12-13
CA2927334A1 (en) 2015-06-11
UA123893C2 (uk) 2021-06-23
BR112016008356A2 (pt) 2017-08-01
WO2015083181A3 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
CL2016000880A1 (es) Recubrimiento farmacéutico soluble en agua con estabilidad mejorada
BR112018073703A2 (pt) emplastro para pele ou ferida, composição farmacêutica e método para a liberação de uma substância ativa
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
MX2015012302A (es) Composiciones tópicas y métodos de tratamiento para trastornos de la piel.
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
DOP2017000162A (es) Forma de dosificación que incluye una solución sólida de drogas amorfas
MX391216B (es) Composicion farmaceutica que comprende un vector adenoviral.
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
IN2012DE00337A (enExample)
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
BR112015030431A2 (pt) formulação de liberação modificada
EA201792143A1 (ru) Лекарственная форма для продленного высвобождения действующих веществ
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
MX373714B (es) Composiciones de ketoprofeno de accion prolongada.
EA201691825A1 (ru) Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта)
BR112016002165A2 (pt) formulações compreendendo esfinganina
BR112016011999A2 (pt) Derivados de amida para agonista de gpr119
BR112016018624A2 (pt) Artigo e método para sua fabricação
CY1121708T1 (el) Ενωσεις ουριας ινδανυλιου που αναστελλουν την ρ38 map kιναση
JP2019058545A5 (enExample)
BR112016026422A2 (pt) solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson
NZ730713A (en) Dissolution testing of hydrophobic active pharmaceutical ingredients such as avermectins with or without pyrantel